Results 231 to 240 of about 278,227 (245)

Role of Lysyl Oxidase-Like Protein 3 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts. [PDF]

Invest Ophthalmol Vis Sci
Park SH, Choi SH, Park HY, Ko J, Yoon JS.   +4 more
europepmc   +1 more source

A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy. [PDF]

Front Genet
Chng CL, Lai OF, Seah LL, Yong KL, Chung YH, Goh R, Lim CK.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor

Thyroid, 2023
Background: Graves' orbitopathy (GO) is a disfiguring and sight-threatening autoimmune disease. Previous studies have shown the infiltration of macrophages in GO orbital connective tissues.
Yi Lu, Yi Wang, Yang Wang, Yu Wu, Yazhuo Huang, Xingtong Liu, Shuo Zhang, Sisi Zhong, Yinwei Li, Bin Li, Jing Sun, S. Fang, Huifang Zhou   +12 more
semanticscholar   +1 more source

Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy

Thyroid, 2023
Background: In Graves' orbitopathy (GO), localized orbital inflammation within the fixed orbit often leads to a fibrotic phenotype resulting in restrictive myopathy or refractory proptosis.
JaeSang Ko, Yong Joon Kim, Soo Hyun Choi, Christopher Seungkyu Lee, Jina Yoon   +4 more
semanticscholar   +1 more source

Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves’ Orbitopathy: A Retrospective Cohort Study

Thyroid
Background: Treatment for Graves’ hyperthyroidism (GH) in patients with Graves’ orbitopathy (GO) remains a topic of debate. This study aimed to investigate the outcome of GO following glucocorticoids, depending on the chosen thyroid treatment.
G. Cosentino, G. Lanzolla, Simone Comi, M. N. Maglionico, C. Posarelli, Dalì Antonia Ciampa, F. Menconi, R. Rocchi, F. Latrofa, Michele Figus, F. Santini, Michele Marinò   +11 more
semanticscholar   +1 more source

Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?

Ophthalmic Plastic and Reconstructive Surgery, 2023
Purpose: To summarize the development, nomenclature, and rationale of the reported use of monoclonal antibodies (Mabs) in Graves Orbitopathy (GO) and to undertake a systematic review of the management of GO with Mabs.
Naiara F. Xavier, Daniela Tavares Lucena, Antonio A. V. Cruz   +2 more
semanticscholar   +1 more source

Statins in Graves Orbitopathy: A New Therapeutic Tool

Ophthalmic Plastic and Reconstructive Surgery, 2023
Purpose: Graves orbitopathy (GO) is the most common extrathyroidal manifestation of Graves disease. Although its pathogenesis is not fully elucidated, GO is commonly considered an autoimmune disease due to loss of self-tolerance against autoantigens ...
Giulia Lanzolla, Simone Comi, G. Cosentino, Farzad Pakdel, Michele Marinò   +4 more
semanticscholar   +1 more source

Statin Use and the Risk of Graves’ Orbitopathy: A Nationwide Population-Based Cohort Study

Thyroid
Background: Statin use is reported to reduce the risk of Graves’ orbitopathy (GO) in Western populations. However, study regarding the protective effect of statins against GO in Asians with Graves’ disease (GD) is scarce.
Yu-Tsung Chou, Chun-Chieh Lai, Chung-Yi Li, W-C Shen, Yu-Tung Huang, Yi-Lin Wu, Yi-Hsuan Lin, Deng-Chi Yang, Yi-Ching Yang   +8 more
semanticscholar   +1 more source

Endokrine Orbitopathie

Der Internist, 2011
Graves ’ Orbitopathy, A. Eckstein, J. Esser   +2 more
semanticscholar   +1 more source